Andrew R Draganski
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$3.7MFederal grants as PI10 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
10 awards · $3.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 2, 2026 | NIH | STTR Phase I Development and optimization of a nitric oxide releasing microparticle formulation for the topical treatment of chronic rhinosinusitis | $300K | Zylo Therapeutics Inc. |
| Sep 12, 2025 | NIH | STTR Phase I Development and optimization of a nitric oxide releasing microparticle formulation for the topical treatment of chronic rhinosinusitis | $300K | Zylo Therapeutics Inc. |
| Jul 18, 2024 | NIH | STTR Phase I Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus. | $146K | Zylo Therapeutics Inc. |
| Jul 17, 2023 | NIH | STTR Phase I Development and optimization of a nitric oxide releasing microparticle-basedtopical treatment for onychomycosis | $300K | Zylo Therapeutics Inc. |
| May 25, 2023 | NIH | STTR Phase I Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus. | $148K | Zylo Therapeutics Inc. |
| Sep 12, 2022 | NIH | STTR Phase I Optimization of a nanoparticle-based topical PDE5i formulation for treatment of erectile dysfunction | $263K | Zylo Therapeutics Inc. |
| Aug 18, 2022 | NIH | STTR Phase I Development and optimization of a nitric oxide releasing microparticle-basedtopical treatment for onychomycosis | $300K | Zylo Therapeutics Inc. |
| Jul 25, 2022 | NIH | SBIR Phase II Development of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors | $1.0M | Zylo Therapeutics Inc. |
| Jul 19, 2021 | NIH | SBIR Phase II Development of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors | $697K | Zylo Therapeutics Inc. |
| Sep 13, 2019 | NIH | STTR Phase I Optimization of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors | $225K | Zylo Therapeutics Inc. |
Peer ranks
Federal funding#451
Awards as PI#128
Patents#273
Companies
- Zylo Therapeutics Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.